Publication number: 20230393136
Abstract: The present invention relates to the field of cancer. Specifically, the present invention provides compositions and methods useful for detecting and treating aggressive prostate cancer. In another embodiment, a method for identifying a subject as having aggressive prostate cancer comprises the step of measuring one or more of ACPP, CD63, KLK 11, ATRN, GP2, PTPRN2, NPTN, RNASE2, CPE, SERPINA1, DSC2, PTGDS, GRN, LRG1, UMOD, CLU, LOX, ORM1, CD97, PSA and AFM in a urine sample obtained from the subject, wherein a decreased level of one or more of ACPP, CD63, KLK 11, ATRN, GP2, PTPRN2, NPTN, RNASE2, PSA, CPE and/or an increased level of one or more of SERPINA1, DSC2, PTGDS, GRN, LRG1, UMOD, CLU, LOX, ORM1, CD97, and AFM relative to a control identifies the subject as having aggressive prostate cancer. In another embodiment, the method further comprises the step of treating the subject with a prostate cancer therapy.
Type:
Application
Filed:
August 30, 2021
Publication date:
December 7, 2023
Inventors:
Hui Zhang, Mingming Dong, Mamie Lih